CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, ...

Flu season is here and a covid uptick is around the corner. Two infectious diseases experts offer their tips on how to plan for vaccination against those viruses.

What sets Imunon's technology apart is its rare dual application. The proprietary PlaCCine platform is a non-viral DNA technology being developed to target both infectious diseases and oncology ...

Over the past five years, 800 million people worldwide have been infected with COVID-19. The death toll has reached 7 million. Even now, deaths continue to occur. COVID-19 is now trending toward ...

I rate AbbVie stock as a Strong Buy, based on its FDA approval of Rinvoq. Read the latest analysis on the stock here.

I recently received a blast email from a classmate, friend, lawyer, father and former president of the Boston City Council, ...

Oral Presentation Title: Development of a PlaCCine DNA Technology for Safe, Effective and Durable Vaccines Presenting Author: Douglas V. Faller, M.D., Ph.D., Chief Medical Officer, IMUNON Date and ...

Enables accurate analysis of protein complexes, nucleic acids, and gene delivery vehicles, including distinguishing between ...

Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, ...

Then, demand for its COVID-19 vaccine started to diminish. As hospitals resumed normal operations and anti-vaccine sentiment ...

Studies are sounding alarm bells regarding the safety of COVID-19 mRNA vaccines, particularly in light of new findings linking these injections to an increased risk of myocarditis, a potentially fatal ...